Contineum Therapeutics (CTNM) EBT Margin (2023)

Contineum Therapeutics (CTNM) posted quarterly EBT Margin of 84.6% for Q2 2023.

Contineum Therapeutics (CTNM) EBT Margin (2023) Analysis & Trends

Contineum Therapeutics' EBT Margin history runs 1 years deep, the most recent figure standing at 84.6% for Q2 2023.

In Q2 2023, EBT Margin changed N/A year-over-year to 84.6%; the TTM figure through Jun 2024 stood at 63.45% (changed N/A YoY), while the FY2023 annual figure was 46.34%, changed N/A from the prior year.
EBT Margin for Q2 2023 stood at 84.6%.
The five-year high for EBT Margin was 84.6% in Q2 2023, with the low at 84.6% in Q2 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	35.61%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	34.77%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	18.33%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-94.22%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.77%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-2.67%
10	Contineum Therapeutics	533.73 Mn	533.73 Mn	-	-

Historic Data

Download Data

Date	Value
Jun 30, 2023	84.60%